Outcomes of patients treated with the everolimus- versus the zotarolimus-eluting stents in a consecutive cohort of patients at a tertiary medical center




Background


In this study we compare the outcomes of the everolimus-eluting stent (EES) versus the zotarolimus-eluting stent (ZES) treated patients at a tertiary medical center and up to one year follow up.




Methods


Unselected consecutive 196 patients (341 vessels, 404 segments) stented with ZES and 189 patients (308 vessels, 409 segments) stented with EES were retrospectively analyzed for demographic, clinical, angiographic, and procedural variables. One-year follow up was achieved by phone calls and medical records. The first 100 consecutive patients in each cohort underwent SYNTAX scoring by a blinded physician to the type of stent used and clinical variables. Patients with bypass graft treatment were excluded. The primary endpoint of the study was target vessel failure (TVF) defined as the combined endpoint of cardiac death, non fatal myocardial infarction, or target lesion revascularization (TLR). Secondary endpoints included TLR, acute stent thrombosis (ST) as defined by the academic research consortium (ARC), total death, cardiac death, and non fatal myocardial infarction (MI). Descriptive and univariate analyses were performed using t testing for continuous variables (mean ± SD) and χ 2 testing for dichotomous variables (percentages). Kaplan–Meier analysis was carried out for TVF survival.




Methods


Unselected consecutive 196 patients (341 vessels, 404 segments) stented with ZES and 189 patients (308 vessels, 409 segments) stented with EES were retrospectively analyzed for demographic, clinical, angiographic, and procedural variables. One-year follow up was achieved by phone calls and medical records. The first 100 consecutive patients in each cohort underwent SYNTAX scoring by a blinded physician to the type of stent used and clinical variables. Patients with bypass graft treatment were excluded. The primary endpoint of the study was target vessel failure (TVF) defined as the combined endpoint of cardiac death, non fatal myocardial infarction, or target lesion revascularization (TLR). Secondary endpoints included TLR, acute stent thrombosis (ST) as defined by the academic research consortium (ARC), total death, cardiac death, and non fatal myocardial infarction (MI). Descriptive and univariate analyses were performed using t testing for continuous variables (mean ± SD) and χ 2 testing for dichotomous variables (percentages). Kaplan–Meier analysis was carried out for TVF survival.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Nov 16, 2017 | Posted by in CARDIOLOGY | Comments Off on Outcomes of patients treated with the everolimus- versus the zotarolimus-eluting stents in a consecutive cohort of patients at a tertiary medical center

Full access? Get Clinical Tree

Get Clinical Tree app for offline access